Last reviewed · How we verify
DE-117 Ophthalmic Solution
DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
DE-117 is a selective rho kinase (ROCK) inhibitor that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. Used for Glaucoma and ocular hypertension.
At a glance
| Generic name | DE-117 Ophthalmic Solution |
|---|---|
| Sponsor | Santen Inc. |
| Drug class | Rho kinase (ROCK) inhibitor |
| Target | ROCK1/ROCK2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
ROCK inhibitors work by relaxing the cytoskeleton of trabecular meshwork and Schlemm's canal cells, thereby improving aqueous humor drainage through the uveoscleral pathway. This mechanism helps lower intraocular pressure in glaucoma and ocular hypertension patients. DE-117 is formulated as an ophthalmic solution for topical ocular administration.
Approved indications
- Glaucoma and ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Ocular discomfort
Key clinical trials
- A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT (PHASE3)
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study (PHASE3)
- DE-117 Spectrum 5 Study (PHASE3)
- A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study (PHASE3)
- Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6 (PHASE2)
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT (PHASE1, PHASE2)
- Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |